Princeton-based pharma Bristol Myers Squibb is planning another round of layoffs in New Jersey as part of a broader restructuring plan. In a filing with the state Department of Labor & Workforce ...

Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion. Sales decreased 6% year-over-year, or 4% when adjusted for ...

I will continue by comparing the revenue growth rates of Merck and Bristol-Myers Squibb, how often these two giants beat Wall Street analysts' expectations, and also compare their price-to-sales ...

Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise ...

Sandra Leung, one of the longest-serving legal chiefs in the pharmaceutical industry, plans to retire from Bristol Myers Squibb in 2025 after nearly 33 years with the company. Leung will be ...

Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot expectations. Bristol expects sales of about $45.5 billion in 2025 ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know. Bristol-Myers Squibb beat analysts’ revenue ...

Jefferies analyst Akash Tewari upgraded Bristol-Myers Squibb from Hold to Buy and raised the price target to $70 Tewari highlighted strong sales expectations for Cobenfy and improved financial ...

Bristol-Myers Squibb Company (NYSE:BMY) has announced that it will be increasing its periodic dividend on the 3rd of February to $0.62, which will be 3.3% higher than last year's comparable ...

Bristol Myers’ lawsuit asserts that manufacturers can choose between rebate and discount pricing models under the 340B statute. Bristol Myers highlights issues like drug diversion and duplicate ...

Sept 30 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval ...

An attorney for Bristol Myers Squibb on Friday urged a New York federal judge to dismiss a $6.4 billion action against the pharmaceutical giant, claiming the plaintiff has no subject matter ...